Free Trial

Insmed (INSM) Financials

Insmed logo
$72.53 +2.33 (+3.31%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$72.66 +0.13 (+0.18%)
As of 04/17/2025 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Insmed

Annual Income Statements for Insmed

This table shows Insmed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-118 -176 -193 -324 -254 -294 -435 -482 -750 -914
Consolidated Net Income / (Loss)
-118 -176 -193 -324 -254 -294 -435 -482 -750 -914
Net Income / (Loss) Continuing Operations
-118 -176 -193 -324 -254 -294 -435 -482 -750 -914
Total Pre-Tax Income
-120 -176 -193 -324 -254 -293 -436 -480 -747 -910
Total Operating Income
-117 -173 -189 -307 -235 -265 -375 -457 -710 -878
Total Gross Profit
0.00 0.00 0.00 7.41 112 125 144 190 240 278
Total Revenue
0.00 0.00 0.00 9.84 136 164 188 245 305 364
Operating Revenue
0.00 - 0.00 9.84 136 164 188 245 305 364
Total Cost of Revenue
0.00 0.00 0.00 2.42 24 40 44 55 66 86
Operating Cost of Revenue
- 0.00 0.00 2.42 24 40 44 55 66 86
Total Operating Expenses
117 173 189 315 348 390 519 648 949 1,156
Selling, General & Admin Expense
43 51 79 168 211 204 234 266 345 461
Research & Development Expense
74 123 110 145 132 181 273 398 571 598
Amortization Expense
- 0.00 0.00 1.25 4.99 5.00 5.05 5.05 5.05 5.05
Other Special Charges / (Income)
- - - - 0.00 0.00 7.33 -21 29 92
Total Other Income / (Expense), net
-2.92 -3.38 -5.63 -17 -18 -27 -61 -21 -37 -32
Interest Expense
2.89 3.50 5.93 28 28 30 58 26 82 85
Interest & Investment Income
- - - 10 9.92 1.70 - 11 42 53
Other Income / (Expense), net
-0.03 0.12 0.30 0.60 -0.53 0.41 -3.33 -5.94 2.18 0.03
Income Tax Expense
-1.97 0.10 -0.27 0.20 0.78 1.40 -1.76 1.38 2.56 3.71
Basic Earnings per Share
($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57)
Weighted Average Basic Shares Outstanding
58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 112.11M 123.04M 140.43M 164.04M
Diluted Earnings per Share
($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57)
Weighted Average Diluted Shares Outstanding
58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 112.11M 123.04M 140.43M 164.04M
Weighted Average Basic & Diluted Shares Outstanding
58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 118.90M 136.41M 148.49M 181.00M

Quarterly Income Statements for Insmed

This table shows Insmed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-131 -160 -160 -247 -160 -183 -157 -302 -221 -234
Consolidated Net Income / (Loss)
-131 -160 -160 -245 -159 -186 -314 -301 -221 -78
Net Income / (Loss) Continuing Operations
-131 -160 -160 -245 -159 -186 -157 -301 -221 -236
Total Pre-Tax Income
-131 -160 -159 -244 -158 -185 -157 -300 -220 -234
Total Operating Income
-128 -151 -148 -236 -148 -178 -146 -289 -213 -230
Total Gross Profit
54 46 51 61 62 65 58 69 72 78
Total Revenue
68 59 65 77 79 84 76 90 93 104
Operating Revenue
68 59 65 77 79 84 76 90 93 104
Total Cost of Revenue
13 13 14 17 17 18 17 21 21 26
Operating Cost of Revenue
13 13 14 17 17 18 17 21 21 26
Total Operating Expenses
182 198 200 296 210 244 204 358 286 309
Selling, General & Admin Expense
76 73 80 84 91 90 93 107 119 143
Research & Development Expense
100 125 128 197 109 137 121 147 151 180
Amortization Expense
1.26 1.26 1.26 1.26 1.26 1.26 1.26 1.26 1.26 1.26
Other Special Charges / (Income)
5.24 -1.80 -9.50 14 9.00 16 -12 104 15 -15
Total Other Income / (Expense), net
-3.08 -6.16 -9.59 -9.94 -9.42 -8.44 -11 -11 -6.08 -3.25
Interest Expense
3.35 16 20 21 20 21 21 21 21 22
Interest & Investment Income
1.79 - 11 11 11 9.85 8.78 10 17 17
Other Income / (Expense), net
-1.51 1.13 -0.11 -0.49 0.29 2.49 1.26 -0.27 -2.01 1.05
Income Tax Expense
0.37 0.13 0.48 0.53 0.54 1.00 0.59 0.84 1.01 1.27
Basic Earnings per Share
($1.09) ($1.22) ($1.17) ($1.78) ($1.11) ($1.28) ($1.06) ($1.94) ($1.27) ($1.30)
Weighted Average Basic Shares Outstanding
120.79M 123.04M 136.36M 137.55M 142.90M 140.43M 148.46M 154.70M 173.72M 164.04M
Diluted Earnings per Share
($1.09) ($1.22) ($1.17) ($1.78) ($1.11) ($1.28) ($1.06) ($1.94) ($1.27) ($1.30)
Weighted Average Diluted Shares Outstanding
120.79M 123.04M 136.36M 137.55M 142.90M 140.43M 148.46M 154.70M 173.72M 164.04M
Weighted Average Basic & Diluted Shares Outstanding
135.48M 136.41M 136.43M 143.80M 143.06M 148.49M 148.60M 171.85M 178.90M 181.00M

Annual Cash Flow Statements for Insmed

This table details how cash moves in and out of Insmed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
124 -120 219 114 -7.64 45 184 357 -592 73
Net Cash From Operating Activities
-101 -147 -160 -258 -251 -219 -363 -400 -536 -684
Net Cash From Continuing Operating Activities
-101 -147 -160 -258 -251 -219 -363 -400 -536 -684
Net Income / (Loss) Continuing Operations
-118 -176 -193 -324 -254 -294 -435 -482 -750 -914
Consolidated Net Income / (Loss)
-118 -176 -193 -324 -254 -294 -435 -482 -750 -914
Depreciation Expense
1.98 2.44 2.90 3.58 5.19 9.15 9.13 5.28 5.53 5.96
Amortization Expense
0.46 0.28 0.12 2.60 25 7.48 8.02 11 15 15
Non-Cash Adjustments To Reconcile Net Income
16 18 19 44 37 61 105 78 204 121
Changes in Operating Assets and Liabilities, net
-0.62 8.64 11 16 -63 -2.95 -51 -13 -11 89
Net Cash From Investing Activities
-3.45 -4.20 -3.00 -15 -42 -6.82 -64 -35 -224 -583
Net Cash From Continuing Investing Activities
-3.45 -4.20 -3.00 -15 -42 -6.82 -64 -35 -224 -583
Purchase of Property, Plant & Equipment
-3.45 -4.20 -3.00 -13 -42 -6.24 -7.29 -9.88 -13 -22
Acquisitions
- 0.00 0.00 -1.72 0.00 -0.58 -6.70 0.00 3.42 0.00
Purchase of Investments
- - - - 0.00 0.00 -50 -100 -589 -1,577
Sale and/or Maturity of Investments
- - - - - 0.00 0.00 75 375 1,016
Net Cash From Financing Activities
228 31 381 387 285 271 613 793 168 1,341
Net Cash From Continuing Financing Activities
228 31 381 387 285 271 613 793 168 1,341
Repayment of Debt
-0.25 -0.41 0.00 -72 4.50 -0.94 -253 -18 -1.22 -3.74
Issuance of Debt
0.00 30 0.00 450 0.00 0.00 575 350 0.00 150
Issuance of Common Equity
223 0.00 378 0.00 261 246 270 292 152 1,084
Other Financing Activities, net
5.11 1.08 3.43 8.82 20 26 21 169 17 111
Effect of Exchange Rate Changes
0.00 -0.05 0.10 -0.05 -0.00 0.49 -0.93 -1.00 -0.25 -1.31
Cash Interest Paid
2.95 3.61 5.17 6.29 7.88 9.19 11 10 36 41
Cash Income Taxes Paid
-3.01 0.09 0.17 0.15 0.34 0.81 1.56 1.72 1.96 2.50

Quarterly Cash Flow Statements for Insmed

This table details how cash moves in and out of Insmed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-1.45 659 -105 -356 -126 -4.74 113 651 -785 94
Net Cash From Operating Activities
-90 -103 -146 -123 -136 -131 -184 -123 -181 -196
Net Cash From Continuing Operating Activities
-90 -103 -146 -123 -136 -131 -184 -123 -181 -196
Net Income / (Loss) Continuing Operations
-131 -160 -160 -245 -159 -186 -157 -301 -221 -236
Consolidated Net Income / (Loss)
-131 -160 -160 -245 -159 -186 -157 -301 -221 -236
Depreciation Expense
0.85 2.18 1.25 1.31 1.49 1.48 1.59 1.44 1.46 1.48
Amortization Expense
2.57 2.90 3.67 3.95 3.78 3.69 3.79 3.74 3.43 3.69
Non-Cash Adjustments To Reconcile Net Income
17 23 37 107 31 29 37 30 32 22
Changes in Operating Assets and Liabilities, net
21 29 -29 10 -14 21 -69 143 2.80 12
Net Cash From Investing Activities
49 20 42 -274 7.15 1.80 295 -6.78 -1,003 132
Net Cash From Continuing Investing Activities
49 20 42 -274 7.15 1.80 295 -6.78 -1,003 132
Purchase of Property, Plant & Equipment
-0.58 -4.69 -3.40 -4.88 -2.85 -2.15 -4.68 -6.78 -3.69 -6.77
Purchase of Investments
- - - - 0.00 -296 - - -1,000 -577
Sale and/or Maturity of Investments
50 25 45 20 10 300 300 - - 716
Net Cash From Financing Activities
37 743 -0.40 44 1.25 123 3.02 781 397 159
Net Cash From Continuing Financing Activities
37 743 -0.40 44 1.25 123 3.02 781 397 159
Repayment of Debt
- -18 -1.22 - - - 0.00 - - -3.74
Issuance of Common Equity
33 259 - - - 114 - - 371 -0.01
Other Financing Activities, net
3.73 152 0.82 6.31 1.25 8.80 3.43 68 26 13
Effect of Exchange Rate Changes
- -1.14 -0.03 -3.40 2.17 1.01 -0.95 -0.69 1.84 -1.51
Cash Interest Paid
2.44 2.72 12 7.90 7.97 8.33 8.21 8.49 8.63 15
Cash Income Taxes Paid
0.43 0.09 1.00 0.36 0.52 0.08 1.21 0.35 0.69 0.25

Annual Balance Sheets for Insmed

This table presents Insmed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
357 238 462 605 742 796 1,244 1,656 1,330 2,025
Total Current Assets
288 168 389 519 555 623 837 1,273 929 1,622
Cash & Equivalents
283 163 381 495 487 533 717 1,074 482 555
Short-Term Investments
- - - - - - 0.00 74 298 879
Accounts Receivable
- - 0.00 5.52 19 17 24 30 41 52
Inventories, net
- - 0.00 7.03 28 50 67 70 83 99
Prepaid Expenses
5.24 5.82 8.28 11 20 24 29 25 24 37
Plant, Property, & Equipment, net
8.09 10 12 23 60 54 53 56 65 80
Total Noncurrent Assets
60 60 60 63 127 119 354 327 335 324
Noncurrent Note & Lease Receivables
- - - 0.00 15 10 9.26 24 21 18
Goodwill
- - - - - 0.00 136 136 136 136
Intangible Assets
58 58 58 59 54 49 74 69 64 59
Other Noncurrent Operating Assets
2.15 1.33 1.97 4.30 58 60 84 98 115 110
Total Liabilities & Shareholders' Equity
357 238 462 605 742 796 1,244 1,656 1,330 2,025
Total Liabilities
45 83 101 396 481 520 833 1,568 1,662 1,740
Total Current Liabilities
22 28 45 80 85 119 135 190 226 298
Accounts Payable
7.47 10 15 18 13 43 125 182 215 285
Other Current Liabilities
0.68 0.73 0.65 1.53 13 13 10 8.13 11 12
Total Noncurrent Liabilities
23 55 56 317 395 401 698 1,378 1,436 1,442
Long-Term Debt
22 55 56 317 336 356 567 1,125 1,155 1,103
Other Noncurrent Operating Liabilities
0.57 0.69 0.77 0.00 59 45 131 253 281 339
Total Equity & Noncontrolling Interests
312 154 361 208 262 276 410 88 -332 285
Total Preferred & Common Equity
312 154 361 208 262 276 410 88 -332 285
Total Common Equity
312 154 361 208 262 276 410 88 -332 285
Common Stock
901 920 1,319 1,490 1,798 2,106 2,675 2,784 3,115 4,648
Retained Earnings
-589 -765 -958 -1,282 -1,536 -1,831 -2,265 -2,697 -3,446 -4,360
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.07 -0.00 -0.01 -0.01 0.19 0.97 0.76 -0.75 -2.29

Quarterly Balance Sheets for Insmed

This table presents Insmed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
995 1,518 1,439 1,325 1,159 1,810 2,053
Total Current Assets
632 1,129 1,052 927 759 1,418 1,650
Cash & Equivalents
415 969 613 487 596 1,247 461
Short-Term Investments
99 30 305 299 0.00 0.00 1,006
Accounts Receivable
27 31 31 36 37 40 42
Inventories, net
66 71 77 78 83 90 98
Prepaid Expenses
25 29 26 27 43 41 41
Plant, Property, & Equipment, net
54 60 62 65 69 73 75
Total Noncurrent Assets
309 329 325 334 332 319 328
Noncurrent Note & Lease Receivables
17 23 22 22 20 20 19
Goodwill
136 136 136 136 136 136 136
Intangible Assets
70 67 66 65 62 61 60
Other Noncurrent Operating Assets
86 102 100 111 113 102 113
Total Liabilities & Shareholders' Equity
995 1,518 1,439 1,325 1,159 1,810 2,053
Total Liabilities
1,025 1,562 1,595 1,614 1,624 1,771 1,570
Total Current Liabilities
138 188 204 197 421 524 259
Accounts Payable
132 179 198 188 189 291 249
Other Current Liabilities
5.79 8.98 6.60 8.95 7.30 8.86 11
Total Noncurrent Liabilities
887 1,374 1,391 1,418 1,203 1,247 1,310
Long-Term Debt
785 1,132 1,140 1,148 939 947 955
Other Noncurrent Operating Liabilities
102 242 251 270 264 300 356
Total Equity & Noncontrolling Interests
-30 -45 -156 -289 -465 39 483
Total Preferred & Common Equity
-30 -45 -156 -289 -465 39 483
Total Common Equity
-30 -45 -156 -289 -465 39 483
Common Stock
2,508 2,811 2,947 2,973 3,140 3,945 4,607
Retained Earnings
-2,536 -2,856 -3,101 -3,260 -3,603 -3,904 -4,124
Accumulated Other Comprehensive Income / (Loss)
-1.39 1.08 -1.25 -2.08 -1.64 -2.83 0.55

Annual Metrics and Ratios for Insmed

This table displays calculated financial ratios and metrics derived from Insmed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 1,287.56% 20.48% 14.63% 30.19% 24.39% 19.17%
EBITDA Growth
-34.19% -48.20% -8.82% -61.94% 31.51% -20.57% -45.56% -23.72% -53.66% -24.86%
EBIT Growth
-34.74% -47.44% -8.85% -62.62% 23.13% -12.32% -42.89% -22.42% -52.71% -24.14%
NOPAT Growth
-34.49% -47.58% -8.95% -62.68% 23.46% -12.75% -41.42% -21.92% -55.17% -23.76%
Net Income Growth
-49.30% -49.15% -9.29% -68.33% 21.57% -15.63% -47.80% -10.79% -55.66% -21.91%
EPS Growth
-9.78% -41.09% -1.40% -46.02% 28.67% 0.00% -28.90% -0.77% -36.57% -4.31%
Operating Cash Flow Growth
-56.33% -45.69% -8.80% -61.62% 2.84% 12.49% -65.63% -10.22% -33.91% -27.53%
Free Cash Flow Firm Growth
-31.97% -35.29% -6.07% -73.05% -17.04% 28.63% -113.44% 53.18% -171.58% -10.95%
Invested Capital Growth
4.04% -13.49% -24.04% -16.10% 270.34% -9.75% 111.40% -69.12% -33.85% -204.94%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 35.66% -2.54% 8.47% 1.31% 8.69% 6.05%
EBITDA Q/Q Growth
-8.73% -25.34% 0.97% -7.38% 22.47% -35.07% -8.51% -6.43% -3.83% -5.39%
EBIT Q/Q Growth
-8.80% -24.80% 0.93% -7.88% 14.60% -21.44% -2.05% -11.72% -3.73% -6.46%
NOPAT Q/Q Growth
-8.82% -24.80% 0.89% -7.85% 14.73% -21.79% -1.23% -12.94% -3.92% -6.31%
Net Income Q/Q Growth
-13.00% -26.71% 1.54% -8.79% 13.17% -20.10% -2.54% -10.85% -3.58% 10.54%
EPS Q/Q Growth
-8.02% -27.23% 7.37% -7.93% 17.31% -17.12% 1.02% -7.12% -1.14% -0.36%
Operating Cash Flow Q/Q Growth
-16.98% -26.15% 5.75% -9.30% 9.32% -11.37% -5.01% -4.99% -5.44% -10.53%
Free Cash Flow Firm Q/Q Growth
-9.53% -18.90% 5.05% -10.72% 4.57% -1.42% -4.92% 43.44% -53.82% -10.57%
Invested Capital Q/Q Growth
1.27% -10.21% -22.94% -16.65% 10.84% -16.74% -2.62% -73.12% -40.53% -51.93%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 75.36% 82.26% 75.75% 76.57% 77.53% 78.52% 76.43%
EBITDA Margin
0.00% 0.00% 0.00% -3,056.02% -150.84% -150.96% -191.70% -182.17% -225.04% -235.80%
Operating Margin
0.00% 0.00% 0.00% -3,124.94% -172.38% -161.32% -199.03% -186.39% -232.51% -241.47%
EBIT Margin
0.00% 0.00% 0.00% -3,118.82% -172.77% -161.07% -200.80% -188.81% -231.79% -241.46%
Profit (Net Income) Margin
0.00% 0.00% 0.00% -3,297.17% -186.37% -178.87% -230.63% -196.26% -245.59% -251.24%
Tax Burden Percent
98.36% 100.06% 99.86% 100.06% 100.31% 100.48% 99.60% 100.29% 100.34% 100.41%
Interest Burden Percent
102.24% 101.67% 102.28% 105.65% 107.54% 110.52% 115.32% 103.65% 105.59% 103.63%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -659.80% -235.35% -177.13% -169.57% -232.69% -921.05% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -616.50% -181.01% -111.00% -78.20% -88.10% -1,064.77% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 545.88% 127.11% 67.72% 42.92% 39.46% 1,535.52% 0.00%
Return on Equity (ROE)
-47.47% -75.62% -74.74% -113.92% -108.24% -109.42% -126.66% -193.22% 614.47% 3,926.49%
Cash Return on Invested Capital (CROIC)
-159.39% -226.74% -294.66% -642.29% -350.31% -166.89% -241.12% -127.07% -880.29% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% -57.52% -35.01% -34.43% -37.11% -31.95% -47.38% -52.35%
Return on Assets (ROA)
0.00% 0.00% 0.00% -60.81% -37.77% -38.23% -42.62% -33.21% -50.20% -54.47%
Return on Common Equity (ROCE)
-47.47% -75.62% -74.74% -113.92% -108.24% -109.42% -126.66% -193.22% 614.47% 3,926.49%
Return on Equity Simple (ROE_SIMPLE)
-37.92% -114.11% -53.36% -155.70% -97.20% -106.60% -105.89% -547.50% 225.83% -320.20%
Net Operating Profit after Tax (NOPAT)
-82 -121 -132 -215 -165 -186 -263 -320 -497 -615
NOPAT Margin
0.00% 0.00% 0.00% -2,187.46% -120.67% -112.92% -139.32% -130.47% -162.75% -169.03%
Net Nonoperating Expense Percent (NNEP)
-18.33% -30.03% -27.88% -43.30% -54.34% -66.13% -91.37% -144.59% 143.72% 1,346.16%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -26.39% -60.33% -44.27%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 24.64% 17.74% 24.25% 23.43% 22.47% 21.48% 23.57%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 1,710.40% 154.47% 123.84% 124.31% 108.33% 112.87% 126.78%
R&D to Revenue
0.00% 0.00% 0.00% 1,477.20% 96.51% 110.18% 144.72% 162.02% 187.09% 164.52%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 3,200.31% 254.64% 237.07% 275.60% 263.92% 311.02% 317.90%
Earnings before Interest and Taxes (EBIT)
-118 -173 -189 -307 -236 -265 -378 -463 -707 -878
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-115 -171 -186 -301 -206 -248 -361 -447 -687 -858
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
3.60 5.30 6.61 4.86 8.15 12.29 7.86 30.78 0.00 43.28
Price to Tangible Book Value (P/TBV)
4.43 8.50 7.89 6.76 10.26 14.96 16.08 0.00 0.00 136.30
Price to Revenue (P/Rev)
0.00 0.00 0.00 102.84 15.63 20.63 17.11 11.03 14.53 33.96
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
16.01 15.23 58.16 28.00 17.99 32.33 14.39 41.34 111.97 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 84.69 14.52 19.55 16.05 10.94 15.75 33.05
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.08 0.35 0.15 1.52 1.28 1.29 1.38 12.79 -3.48 3.87
Long-Term Debt to Equity
0.07 0.35 0.15 1.52 1.28 1.29 1.38 12.79 -3.48 3.87
Financial Leverage
-0.79 -0.78 -0.84 -0.89 -0.70 -0.61 -0.55 -0.45 -1.44 -0.95
Leverage Ratio
1.18 1.28 1.36 1.87 2.87 2.86 2.97 5.82 -12.24 -72.08
Compound Leverage Factor
1.21 1.30 1.39 1.98 3.08 3.16 3.43 6.03 -12.92 -74.70
Debt to Total Capital
7.46% 26.18% 13.34% 60.32% 56.21% 56.36% 57.99% 92.75% 140.31% 79.45%
Short-Term Debt to Total Capital
0.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
6.54% 26.18% 13.34% 60.32% 56.21% 56.36% 57.99% 92.75% 140.31% 79.45%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
92.54% 73.82% 86.66% 39.68% 43.79% 43.64% 42.01% 7.25% -40.31% 20.55%
Debt to EBITDA
-0.22 -0.32 -0.30 -1.05 -1.63 -1.44 -1.57 -2.52 -1.68 -1.29
Net Debt to EBITDA
2.24 0.63 1.75 0.59 0.74 0.71 0.55 0.05 -0.55 0.39
Long-Term Debt to EBITDA
-0.19 -0.32 -0.30 -1.05 -1.63 -1.44 -1.57 -2.52 -1.68 -1.29
Debt to NOPAT
-0.31 -0.45 -0.42 -1.47 -2.04 -1.92 -2.16 -3.52 -2.33 -1.79
Net Debt to NOPAT
3.13 0.89 2.46 0.83 0.92 0.95 0.76 0.07 -0.75 0.54
Long-Term Debt to NOPAT
-0.27 -0.45 -0.42 -1.47 -2.04 -1.92 -2.16 -3.52 -2.33 -1.79
Altman Z-Score
12.50 -0.31 10.83 -2.22 -0.34 0.56 -0.40 -1.23 -2.92 0.78
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
12.94 6.02 8.72 6.51 6.51 5.24 6.19 6.69 4.12 5.45
Quick Ratio
12.71 5.81 8.54 6.28 5.94 4.62 5.48 6.19 3.64 4.99
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-84 -114 -121 -209 -245 -175 -373 -175 -475 -527
Operating Cash Flow to CapEx
-2,915.46% -3,493.05% -5,318.79% -1,970.79% -593.00% -3,515.19% -4,984.25% -4,053.85% -4,035.57% -3,119.47%
Free Cash Flow to Firm to Interest Expense
-29.19 -32.62 -20.43 -7.57 -8.85 -5.92 -6.42 -6.61 -5.81 -6.20
Operating Cash Flow to Interest Expense
-34.86 -41.94 -26.94 -9.32 -9.05 -7.42 -6.25 -15.14 -6.56 -8.05
Operating Cash Flow Less CapEx to Interest Expense
-36.05 -43.14 -27.45 -9.79 -10.57 -7.63 -6.37 -15.52 -6.73 -8.31
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.02 0.20 0.21 0.18 0.17 0.20 0.22
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 11.03 9.19 9.21 9.08 8.61 7.80
Inventory Turnover
0.00 0.00 0.00 0.00 1.37 1.02 0.76 0.81 0.86 0.94
Fixed Asset Turnover
0.00 0.00 0.00 0.56 3.30 2.88 3.53 4.48 5.01 5.00
Accounts Payable Turnover
0.00 0.00 0.00 0.15 1.57 1.42 0.53 0.36 0.33 0.34
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 33.09 39.73 39.62 40.21 42.40 46.77
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 266.42 356.58 481.96 453.32 426.30 387.01
Days Payable Outstanding (DPO)
0.00 0.00 0.00 2,441.27 233.10 256.49 693.94 1,016.84 1,105.20 1,064.66
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 -2,441.27 66.41 139.82 -172.35 -523.30 -636.51 -630.88
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
54 47 35 30 110 99 210 65 43 -45
Invested Capital Turnover
0.00 0.00 0.00 0.30 1.95 1.57 1.22 1.78 5.66 -342.80
Increase / (Decrease) in Invested Capital
2.10 -7.28 -11 -5.71 80 -11 111 -145 -22 -88
Enterprise Value (EV)
864 711 2,063 833 1,982 3,215 3,024 2,684 4,808 12,021
Market Capitalization
1,122 819 2,388 1,011 2,134 3,391 3,224 2,707 4,433 12,351
Book Value per Share
$5.04 $2.50 $4.71 $2.70 $2.93 $2.71 $3.47 $0.65 ($2.32) $1.60
Tangible Book Value per Share
$4.10 $1.56 $3.95 $1.94 $2.33 $2.22 $1.69 ($0.86) ($3.72) $0.51
Total Capital
337 209 417 525 598 632 977 1,213 823 1,389
Total Debt
25 55 56 317 336 356 567 1,125 1,155 1,103
Total Long-Term Debt
22 55 56 317 336 356 567 1,125 1,155 1,103
Net Debt
-258 -108 -326 -179 -151 -176 -200 -23 375 -330
Capital Expenditures (CapEx)
3.45 4.20 3.00 13 42 6.24 7.29 9.88 13 22
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-14 -22 -36 -56 -17 -29 -15 -65 -77 -110
Debt-free Net Working Capital (DFNWC)
269 140 345 439 470 504 702 1,083 703 1,324
Net Working Capital (NWC)
266 140 345 439 470 504 702 1,083 703 1,324
Net Nonoperating Expense (NNE)
36 55 60 109 90 108 172 161 253 299
Net Nonoperating Obligations (NNO)
-258 -108 -326 -179 -151 -176 -200 -23 375 -330
Total Depreciation and Amortization (D&A)
2.44 2.72 3.02 6.18 30 17 17 16 21 21
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% -567.95% -12.81% -17.44% -7.91% -26.55% -25.23% -30.16%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 4,465.83% 344.37% 306.60% 372.42% 441.45% 230.48% 364.07%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 4,465.83% 344.37% 306.60% 372.42% 441.45% 230.48% 364.07%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57)
Adjusted Weighted Average Basic Shares Outstanding
61.86M 62.02M 76.62M 77.54M 89.78M 103.04M 112.11M 123.04M 140.43M 164.04M
Adjusted Diluted Earnings per Share
($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57)
Adjusted Weighted Average Diluted Shares Outstanding
61.86M 62.02M 76.62M 77.54M 89.78M 103.04M 112.11M 123.04M 140.43M 164.04M
Adjusted Basic & Diluted Earnings per Share
($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 118.90M 136.41M 148.49M 181.00M
Normalized Net Operating Profit after Tax (NOPAT)
-82 -121 -132 -215 -165 -186 -257 -335 -477 -551
Normalized NOPAT Margin
0.00% 0.00% 0.00% -2,187.46% -120.67% -112.92% -136.60% -136.41% -156.17% -151.39%
Pre Tax Income Margin
0.00% 0.00% 0.00% -3,295.13% -185.80% -178.02% -231.57% -195.69% -244.76% -250.22%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-40.68 -49.54 -31.83 -11.08 -8.51 -8.96 -6.51 -17.52 -8.66 -10.34
NOPAT to Interest Expense
-28.47 -34.70 -22.32 -7.77 -5.94 -6.28 -4.51 -12.10 -6.08 -7.24
EBIT Less CapEx to Interest Expense
-41.88 -50.74 -32.34 -11.55 -10.04 -9.17 -6.63 -17.89 -8.82 -10.60
NOPAT Less CapEx to Interest Expense
-29.66 -35.90 -22.83 -8.24 -7.47 -6.49 -4.64 -12.48 -6.24 -7.50
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Insmed

This table displays calculated financial ratios and metrics derived from Insmed's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
44.86% 5.66% 22.80% 18.41% 16.75% 41.13% 15.77% 16.98% 18.15% 24.79%
EBITDA Growth
-37.54% -22.84% -64.81% -159.44% -12.97% -17.46% 3.13% -23.07% -48.16% -31.41%
EBIT Growth
-24.13% -47.79% -62.79% -154.82% -14.06% -16.92% 2.72% -22.52% -46.18% -30.48%
NOPAT Growth
-23.24% -52.88% -64.93% -166.69% -15.64% -17.69% 1.79% -22.66% -44.53% -29.25%
Net Income Growth
-16.35% -41.73% -68.85% -155.96% -21.19% -16.20% -96.65% -22.79% -38.75% 57.83%
EPS Growth
-13.54% -27.08% -46.25% -122.50% -1.83% -4.92% 9.40% -8.99% -14.41% -1.56%
Operating Cash Flow Growth
-19.06% -22.60% -39.12% -20.03% -51.77% -26.83% -25.79% -0.13% -32.70% -49.81%
Free Cash Flow Firm Growth
31.92% 121.80% 130.99% 118.64% 157.34% -361.76% -352.69% -406.04% -172.05% 28.72%
Invested Capital Growth
11.88% -69.12% -62.72% -74.85% -70.10% -33.85% 15.63% -155.37% -141.08% -204.94%
Revenue Q/Q Growth
3.85% -12.45% 9.97% 18.42% 2.39% 5.84% -9.79% 19.66% 3.41% 11.79%
EBITDA Q/Q Growth
-41.43% -15.47% 1.31% -60.97% 38.42% -20.06% 22.99% -104.52% 25.86% -6.48%
EBIT Q/Q Growth
-39.50% -16.36% 1.38% -59.18% 37.55% -19.27% 18.09% -100.48% 25.50% -6.47%
NOPAT Q/Q Growth
-44.59% -18.62% 2.19% -58.97% 37.30% -20.72% 18.38% -98.55% 26.12% -7.96%
Net Income Q/Q Growth
-37.12% -22.10% 0.22% -53.23% 35.08% -17.07% -68.86% 4.32% 26.64% 64.42%
EPS Q/Q Growth
-36.25% -11.93% 4.10% -52.14% 37.64% -15.32% 17.19% -83.02% 34.54% -2.36%
Operating Cash Flow Q/Q Growth
12.19% -14.83% -41.84% 16.07% -11.03% 4.04% -40.68% 33.19% -47.14% -8.33%
Free Cash Flow Firm Q/Q Growth
33.86% 134.14% 16.61% -29.21% 103.45% -255.86% -12.57% 14.26% 52.11% -54.19%
Invested Capital Q/Q Growth
-8.36% -73.12% 36.86% -25.39% 8.93% -40.53% 139.24% -135.73% 19.19% -51.93%
Profitability Metrics
- - - - - - - - - -
Gross Margin
80.11% 77.96% 78.79% 78.51% 78.87% 77.96% 76.88% 76.79% 77.34% 74.96%
EBITDA Margin
-185.73% -244.95% -219.82% -298.80% -179.72% -203.86% -183.92% -314.36% -225.37% -214.67%
Operating Margin
-188.54% -255.44% -227.19% -304.97% -186.75% -213.01% -192.72% -319.80% -228.45% -220.61%
EBIT Margin
-190.77% -253.53% -227.36% -305.61% -186.39% -210.03% -191.05% -320.09% -230.60% -219.61%
Profit (Net Income) Margin
-193.63% -270.02% -244.98% -316.99% -201.00% -222.31% -416.14% -332.75% -236.04% -75.12%
Tax Burden Percent
100.28% 100.08% 100.30% 100.22% 100.34% 100.54% 200.75% 100.28% 100.46% 33.49%
Interest Burden Percent
101.21% 106.42% 107.43% 103.50% 107.47% 105.28% 108.50% 103.66% 101.89% 102.14%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-139.75% -318.89% -250.26% -348.78% -234.00% -843.80% -444.30% -4,973.00% -2,577.92% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
338.90% -270.44% -294.75% -385.00% -251.56% -878.63% -504.87% -5,107.30% -2,484.04% 0.00%
Return on Net Nonoperating Assets (RNNOA)
-12.45% 121.14% -987.34% 1,524.01% 498.73% 1,267.09% 694.74% 6,399.51% 1,939.39% 0.00%
Return on Equity (ROE)
-152.20% -197.75% -1,237.60% 1,175.23% 264.73% 423.29% 250.44% 1,426.50% -638.53% 3,926.49%
Cash Return on Invested Capital (CROIC)
-135.15% -127.07% -129.23% -161.70% -196.74% -880.29% -531.09% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-40.06% -42.90% -43.83% -66.08% -45.13% -42.93% -45.04% -64.74% -46.83% -47.61%
Return on Assets (ROA)
-40.66% -45.69% -47.23% -68.54% -48.66% -45.44% -98.09% -67.30% -47.93% -16.29%
Return on Common Equity (ROCE)
-152.20% -197.75% -1,237.60% 1,175.23% 264.73% 423.29% 250.44% 1,426.50% -638.53% 3,926.49%
Return on Equity Simple (ROE_SIMPLE)
1,449.94% 0.00% 1,224.28% 446.78% 250.08% 0.00% 194.49% -2,472.53% -211.28% 0.00%
Net Operating Profit after Tax (NOPAT)
-89 -106 -104 -165 -103 -125 -102 -202 -149 -161
NOPAT Margin
-131.98% -178.81% -159.03% -213.48% -130.73% -149.10% -134.91% -223.86% -159.91% -154.43%
Net Nonoperating Expense Percent (NNEP)
-478.65% -48.45% 44.49% 36.22% 17.55% 34.83% 60.57% 134.29% -93.89% -372.94%
Return On Investment Capital (ROIC_SIMPLE)
- -8.74% - - - -15.16% - - - -11.61%
Cost of Revenue to Revenue
19.89% 22.04% 21.21% 21.49% 21.13% 22.04% 23.12% 23.21% 22.66% 25.04%
SG&A Expenses to Revenue
111.59% 123.91% 122.54% 109.33% 114.61% 106.97% 123.31% 117.96% 127.30% 136.45%
R&D to Revenue
147.46% 210.39% 196.07% 255.05% 138.04% 163.73% 160.37% 162.44% 161.42% 172.08%
Operating Expenses to Revenue
268.65% 333.40% 305.98% 383.49% 265.62% 290.97% 269.60% 396.59% 305.79% 295.58%
Earnings before Interest and Taxes (EBIT)
-129 -150 -148 -236 -147 -176 -144 -289 -215 -229
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-126 -145 -143 -231 -142 -171 -139 -284 -211 -224
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 30.78 0.00 0.00 0.00 0.00 0.00 256.49 25.95 43.28
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.65 136.30
Price to Revenue (P/Rev)
10.67 11.03 9.03 10.68 12.93 14.53 12.30 30.30 36.58 33.96
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
11.82 41.34 27.68 46.77 55.29 111.97 43.30 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
11.79 10.94 9.55 11.51 14.22 15.75 14.10 30.07 35.08 33.05
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
-26.20 12.79 -25.36 -7.32 -3.97 -3.48 -2.50 30.17 1.98 3.87
Long-Term Debt to Equity
-26.20 12.79 -25.36 -7.32 -3.97 -3.48 -2.02 24.39 1.98 3.87
Financial Leverage
-0.04 -0.45 3.35 -3.96 -1.98 -1.44 -1.38 -1.25 -0.78 -0.95
Leverage Ratio
4.86 5.82 35.51 -22.35 -7.26 -12.24 -5.25 -27.79 17.41 -72.08
Compound Leverage Factor
4.92 6.19 38.14 -23.14 -7.81 -12.89 -5.70 -28.81 17.74 -73.63
Debt to Total Capital
103.97% 92.75% 104.11% 115.83% 133.72% 140.31% 166.55% 96.79% 66.39% 79.45%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 32.10% 18.55% 0.00% 0.00%
Long-Term Debt to Total Capital
103.97% 92.75% 104.11% 115.83% 133.72% 140.31% 134.45% 78.24% 66.39% 79.45%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-3.97% 7.25% -4.11% -15.83% -33.72% -40.31% -66.55% 3.21% 33.61% 20.55%
Debt to EBITDA
-1.87 -2.52 -2.25 -1.77 -1.73 -1.68 -1.68 -1.57 -1.17 -1.29
Net Debt to EBITDA
-0.65 0.05 -0.27 -0.34 -0.55 -0.55 -0.82 0.10 0.63 0.39
Long-Term Debt to EBITDA
-1.87 -2.52 -2.25 -1.77 -1.73 -1.68 -1.36 -1.27 -1.17 -1.29
Debt to NOPAT
-2.77 -3.52 -3.14 -2.46 -2.40 -2.33 -2.35 -2.20 -1.65 -1.79
Net Debt to NOPAT
-0.96 0.07 -0.37 -0.48 -0.76 -0.75 -1.15 0.14 0.89 0.54
Long-Term Debt to NOPAT
-2.77 -3.52 -3.14 -2.46 -2.40 -2.33 -1.90 -1.78 -1.65 -1.79
Altman Z-Score
-1.65 -0.61 -1.15 -1.58 -1.59 -1.60 -2.71 0.60 2.62 1.84
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
4.59 6.69 6.01 5.15 4.71 4.12 1.80 2.71 6.37 5.45
Quick Ratio
3.93 6.19 5.48 4.64 4.18 3.64 1.50 2.46 5.83 4.99
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-115 39 46 32 66 -103 -116 -99 -48 -73
Operating Cash Flow to CapEx
-15,434.36% -2,198.87% -4,305.56% -2,514.68% -4,776.91% -6,076.13% -3,933.21% -1,812.65% -4,904.20% -2,893.96%
Free Cash Flow to Firm to Interest Expense
-34.31 2.39 2.29 1.57 3.25 -4.95 -5.50 -4.67 -2.26 -3.40
Operating Cash Flow to Interest Expense
-26.79 -6.27 -7.31 -5.96 -6.72 -6.29 -8.75 -5.78 -8.59 -9.09
Operating Cash Flow Less CapEx to Interest Expense
-26.96 -6.56 -7.48 -6.19 -6.86 -6.40 -8.97 -6.10 -8.77 -9.41
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.21 0.17 0.19 0.22 0.24 0.20 0.24 0.20 0.20 0.22
Accounts Receivable Turnover
10.37 9.08 9.16 8.92 8.92 8.61 9.32 9.22 8.81 7.80
Inventory Turnover
0.83 0.81 0.84 0.79 0.83 0.86 0.90 0.88 0.88 0.94
Fixed Asset Turnover
4.53 4.48 4.59 4.64 4.75 5.01 4.92 4.87 4.90 5.00
Accounts Payable Turnover
0.71 0.36 0.50 0.50 0.38 0.33 0.38 0.30 0.36 0.34
Days Sales Outstanding (DSO)
35.21 40.21 39.87 40.92 40.93 42.40 39.15 39.57 41.45 46.77
Days Inventory Outstanding (DIO)
440.97 453.32 435.51 462.52 437.16 426.30 406.86 415.29 412.53 387.01
Days Payable Outstanding (DPO)
512.40 1,016.84 731.66 733.01 969.04 1,105.20 971.49 1,211.78 1,020.78 1,064.66
Cash Conversion Cycle (CCC)
-36.23 -523.30 -256.28 -229.57 -490.95 -636.51 -525.47 -756.92 -566.79 -630.88
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
242 65 89 66 72 43 103 -37 -30 -45
Invested Capital Turnover
1.06 1.78 1.57 1.63 1.79 5.66 3.29 22.22 16.12 -342.80
Increase / (Decrease) in Invested Capital
26 -145 -150 -197 -169 -22 14 -103 -102 -88
Enterprise Value (EV)
2,856 2,684 2,459 3,101 3,993 4,808 4,449 9,881 12,032 12,021
Market Capitalization
2,584 2,707 2,326 2,879 3,631 4,433 3,881 9,957 12,545 12,351
Book Value per Share
($0.25) $0.65 ($0.33) ($1.14) ($2.01) ($2.32) ($3.13) $0.26 $2.81 $1.60
Tangible Book Value per Share
($1.97) ($0.86) ($1.82) ($2.62) ($3.41) ($3.72) ($4.47) ($1.07) $1.67 $0.51
Total Capital
755 1,213 1,088 984 858 823 698 1,210 1,438 1,389
Total Debt
785 1,125 1,132 1,140 1,148 1,155 1,163 1,171 955 1,103
Total Long-Term Debt
785 1,125 1,132 1,140 1,148 1,155 939 947 955 1,103
Net Debt
272 -23 134 222 362 375 568 -76 -513 -330
Capital Expenditures (CapEx)
0.58 4.69 3.40 4.88 2.85 2.15 4.68 6.78 3.69 6.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-19 -65 -58 -70 -56 -77 -34 -128 -77 -110
Debt-free Net Working Capital (DFNWC)
495 1,083 941 848 730 703 562 1,118 1,391 1,324
Net Working Capital (NWC)
495 1,083 941 848 730 703 338 894 1,391 1,324
Net Nonoperating Expense (NNE)
42 54 56 80 56 61 212 98 71 -83
Net Nonoperating Obligations (NNO)
272 -23 134 222 362 375 568 -76 -513 -330
Total Depreciation and Amortization (D&A)
3.42 5.09 4.91 5.26 5.27 5.17 5.38 5.18 4.89 5.17
Debt-free, Cash-free Net Working Capital to Revenue
-7.76% -26.55% -22.37% -25.83% -19.98% -25.23% -10.67% -39.05% -22.52% -30.16%
Debt-free Net Working Capital to Revenue
204.19% 441.45% 365.52% 314.75% 259.90% 230.48% 178.15% 340.37% 405.49% 364.07%
Net Working Capital to Revenue
204.19% 441.45% 365.52% 314.75% 259.90% 230.48% 107.09% 272.07% 405.49% 364.07%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($1.09) ($1.22) ($1.17) ($1.78) ($1.11) ($1.28) ($1.06) ($1.94) ($1.27) ($1.30)
Adjusted Weighted Average Basic Shares Outstanding
120.79M 123.04M 136.36M 137.55M 142.90M 140.43M 148.46M 154.70M 173.72M 164.04M
Adjusted Diluted Earnings per Share
($1.09) ($1.22) ($1.17) ($1.78) ($1.11) ($1.28) ($1.06) ($1.94) ($1.27) ($1.30)
Adjusted Weighted Average Diluted Shares Outstanding
120.79M 123.04M 136.36M 137.55M 142.90M 140.43M 148.46M 154.70M 173.72M 164.04M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
135.48M 136.41M 136.43M 143.80M 143.06M 148.49M 148.60M 171.85M 178.90M 181.00M
Normalized Net Operating Profit after Tax (NOPAT)
-86 -107 -110 -155 -97 -114 -110 -130 -139 -172
Normalized NOPAT Margin
-126.56% -180.93% -169.23% -201.25% -122.76% -135.97% -145.94% -143.51% -148.91% -164.35%
Pre Tax Income Margin
-193.08% -269.81% -244.24% -316.30% -200.31% -221.12% -207.29% -331.83% -234.96% -224.32%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-38.54 -9.14 -7.41 -11.45 -7.26 -8.46 -6.86 -13.60 -10.23 -10.64
NOPAT to Interest Expense
-26.66 -6.45 -5.18 -8.00 -5.10 -6.00 -4.84 -9.51 -7.10 -7.48
EBIT Less CapEx to Interest Expense
-38.71 -9.43 -7.58 -11.68 -7.41 -8.56 -7.08 -13.92 -10.41 -10.96
NOPAT Less CapEx to Interest Expense
-26.83 -6.73 -5.35 -8.23 -5.24 -6.11 -5.06 -9.83 -7.27 -7.80
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Insmed's Financials

When does Insmed's fiscal year end?

According to the most recent income statement we have on file, Insmed's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Insmed's net income changed over the last 9 years?

Insmed's net income appears to be on an upward trend, with a most recent value of -$913.77 million in 2024, rising from -$118.18 million in 2015. The previous period was -$749.57 million in 2023.

What is Insmed's operating income?
Insmed's total operating income in 2024 was -$878.25 million, based on the following breakdown:
  • Total Gross Profit: $277.97 million
  • Total Operating Expenses: $1.16 billion
How has Insmed revenue changed over the last 9 years?

Over the last 9 years, Insmed's total revenue changed from $0.00 in 2015 to $363.71 million in 2024, a change of 36,370,700,000.0%.

How much debt does Insmed have?

Insmed's total liabilities were at $1.74 billion at the end of 2024, a 4.7% increase from 2023, and a 3,778.6% increase since 2015.

How much cash does Insmed have?

In the past 9 years, Insmed's cash and equivalents has ranged from $162.59 million in 2016 to $1.07 billion in 2022, and is currently $555.03 million as of their latest financial filing in 2024.

How has Insmed's book value per share changed over the last 9 years?

Over the last 9 years, Insmed's book value per share changed from 5.04 in 2015 to 1.60 in 2024, a change of -68.4%.



This page (NASDAQ:INSM) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners